For research teamsHelp me find a study
Back to all studies
Not recruitingEUCTR 2022-001665-12

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

SchizophreniaDrug

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Need help deciding?

Ask HopeStage to help me review this study

This study may no longer be open, but we can help you understand it and find similar studies.

Loading the security check...
Study ID: EUCTR 2022-001665-12. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

EU CTR and CTIS records checked by HopeStage on . Registry information can change. Always confirm availability with the research team.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

View the historical EU CTR record

View the current CTIS record

Current CTIS country statuses
Historical EU CTR country statuses

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Bulgaria · 19 sites
  • Dr. Ivo Natsov Outpatient Clinic For Individual Practice For Specialized Medical Care In Psychiatry ET — N/A
    Cherven Bryag
    Country status: Not recruiting
  • Asclepius Medical Center OOD — N/A
    Dupnitsa
    Country status: Not recruiting
  • Multiprofile Hospital For Active Treatment Dr. Hristo Stambolski EOOD — Department of Psychiatry
    Kazanlik
    Country status: Not recruiting
  • Medical Center Lifemed EOOD — N/A
    Kirdzhali
    Country status: Not recruiting
  • State Psychiatric Hospital Sv. Ivan Rilski - Novi Iskar — General psychiatric department
    Novi Iskar
    Country status: Not recruiting
  • Medical Center Medconsult Pleven OOD — N/A
    Pleven
    Country status: Not recruiting
  • University Multiprofile Hospital For Active Treatment Dr. Georgi Stranski EAD — Psychiatric Clinic
    Pleven
    Country status: Not recruiting
  • Medical Center Mentalcare Ltd. — N/A
    Plovdiv
    Country status: Not recruiting
  • University Multiprofile Hospital For Active Treatment Saint Georgi EAD — Clinic of Psychiatry
    Plovdiv
    Country status: Not recruiting
  • MBAL Dr. Ivan Seliminski - Sliven AD — Department of Psychiatry
    Sliven
    Country status: Not recruiting
  • Medical Center Academica EOOD — N/A
    Sofia
    Country status: Not recruiting
  • Mental Health Center Sofia EOOD — N/A
    Sofia
    Country status: Not recruiting
  • Diagnostic And Consultation Centre St.Vrach And St.St. Kuzma And Damian OOD — N/A
    Sofiya
    Country status: Not recruiting
  • Medical Center Hera EOOD — N/A
    Sofiya
    Country status: Not recruiting
  • Medical Center Intermedica Ltd. — N/A
    Sofiya
    Country status: Not recruiting
  • Medical Center Saint Naum EOOD — N/A
    Sofiya
    Country status: Not recruiting
  • Medical Center VAS OOD — N/A
    Targovishte
    Country status: Not recruiting
  • Diagnostics-Consultancy Center Mladost M Varna OOD — N/A
    Varna
    Country status: Not recruiting
  • Center For Mental Health Vratsa EOOD — N/A
    Vratsa
    Country status: Not recruiting
In plain English

Key information made simple

What the source confirms

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

What should you check before joining?

Check the official protocol for eligibility, treatment, visits and assessments. If recruitment is listed, confirm with the team that a specific centre is still accepting participants before taking any next step.

What to expect

Your next step

Study sites are listed in the registry. Recruitment status can differ between sites. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Not recruiting
Enrollment listed in the registry
400
Sponsor
Karuna Therapeutics, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Bulgaria
Age range
Not clearly listed
Official registry ID
EUCTR 2022-001665-12
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia.
Official source
Official registry link

Ask HopeStage to help me review this study

This study may no longer be open, but we can help you understand it and find similar studies.

Loading the security check...
Study ID: EUCTR 2022-001665-12. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What does the official source confirm?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Is this study recruiting?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

How can I check the participation requirements?

Check the official protocol for the criteria, treatment and planned assessments. The research team must confirm visits, risks, open centres and your eligibility.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.

Drug study icon
Not recruitingEUCTR 2008-002676-10

A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Drug study icon
Not recruitingEUCTR 2008-002699-83

A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.